Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations

Diffuse large B cell lymphoma (DLBCL) frequently harbors genetic alterations that activate the B cell receptor (BCR) and TLR pathways, which converge to activate NF-κB. While selective inhibition of BTK with ibrutinib causes clinical responses in relapsed DLBCL patients, most responses are partial a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCI Insight
Hlavní autoři: Mondello, Patrizia, Brea, Elliott J., De Stanchina, Elisa, Toska, Eneda, Chang, Aaron Y., Fennell, Myles, Seshan, Venkatraman, Garippa, Ralph, Scheinberg, David A., Baselga, José, Wendel, Hans-Guido, Younes, Anas
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358483/
https://ncbi.nlm.nih.gov/pubmed/28352655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.90196
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky